Overview

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

Status:
Unknown status

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety of giving subjects with advanced, recurrent or refractory melanoma the HyperAcute® Melanoma vaccine with a variant of a drug, called Interferon (PEG-Intron®) that is specially formulated to be given on a weekly basis (instead of daily). The study vaccine (HyperAcute®-Melanoma) is made from three types of human melanoma cell lines (grown in the laboratory) in which the genes have been slightly changed. This clinical study will try to discover the safety of the study vaccine combined with PEG-Intron®, its side effects and the potential benefits, if any.

Phase:

Phase 2

Details

Lead Sponsor:

Ochsner Health System

Collaborator:

NewLink Genetics Corporation

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b
Vaccines